Navigation Links
Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
Date:9/11/2008

LAIYANG, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that the Company received purchase orders for a total value of approximately $12 million over the next 12 months from over 800 wholesale distributors at the 43rd Annual New Drugs Conference (the "Conference") sponsored by China Health Tech Forum 2008.

The 43rd Annual New Drugs Conference was held on September 3rd - 5th in Yantai International Expo Center, Shandong Province. The purpose of this industry Conference was to allow pharmaceutical companies in China with new and innovative products to meet and exchange ideas, and to allow pharmaceutical companies to introduce their products to distributors. Genesis distributed a large number of Company brochures at the Conference and received numerous inquiries from distributors.

The Company's newly developed Radix Isatidis Dispersible Tablets, an herbal-based traditional Chinese medicine, received the highest number of orders, over 60% of the total value of the purchase orders.

"We are pleased that the 43rd Annual New Drugs Conference was such a success for the Company. We believe that these new purchase orders from these distributors will increase our presence in the Chinese over the counter pharmaceuticals market," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises. "We hope to expand our market share and get even greater brand recognition in China in the future by bringing new and innovative products to market."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung, CFO

Tel: +1-954-727-8435

Email: genesispharm@gmail.com

Web: http://www.genesis-china.net

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. EURYI project to understand how the brain wires during embryogenesis
3. DNA damage response confers a barrier for viral tumorigenesis
4. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
5. The genetics of MLL leukemogenesis
6. Genesis Technology Group Retains CCG Elite
7. Researchers chart the genetic mechanisms behind the genesis of fat cells
8. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
9. ThermoGenesis Corp. Reports First Quarter 2008 Results
10. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
11. Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... Agreements being discussed by President Donald Trump and the rest of the world. Donald ... up peace talks in the continuous battle between Israel and Palestine. The world’s eyes ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and ... the series is on hiking in American. Viewers can reconnect with America as it ... of hiking. , Many consumers have looked for an inventive new place for a ...
(Date:5/26/2017)... ... , ... “When the Stars Lead Home”: a poignant story of loss, determination, ... Weigel Douglas, an avid reader who lives in the Pacific Northwest with her husband, ... Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration Contractors ... its 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, ... , As part of BluSky’s partnership with The Adoption Exchange, BluSky will also ...
(Date:5/26/2017)... ... ... Jack: Against All Odds”: the story of Coach Cactus Jack and the impact he ... creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and pharmacy ... Walter and Jane have three adult children and a granddaughter. Walter and ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/10/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... fiscal second quarter ended April 1, 2017 .   ... 666.7% compared to the prior year period as the ... significant gain, while non-GAAP diluted EPS of $0.50 increased ... in constant currency terms.  Excluding the effects of blood ...
(Date:5/9/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... has earned a spot on Forbes, "America,s ... ranked among 500 U.S. employers as well as in ... Services. The annual Forbes rankings ... of over 30,000 employees across 25 industries. The survey ...
Breaking Medicine Technology: